{"id":"thesis-glp1-obesity","category":"thesis","title":"GLP-1 Obesity Drug Supercycle","summary":"Expanding indications, oral formulations, and second-order effects on retail/food.","trigger":{"always":false,"sectors":["Health Care","Healthcare","Consumer Staples","Consumer Discretionary"],"tickers":["LLY","NVO","VKTX","ISRG","UNH","PG","KO","PEP","MCD"],"regimes":[]},"ttl_hours":336,"content":{"thesis":"GLP-1 receptor agonists are expanding beyond weight management into cardiovascular, renal, and neurological indications, creating an unprecedented healthcare wave. Oral formulations launching in mid-2026 are massively expanding the addressable market as production bottlenecks ease.","primary_beneficiaries":{"LLY":"Market leader with Zepbound, Mounjaro, and triple-agonist retatrutide in pipeline","NVO":"Pioneer with Wegovy/Ozempic and advanced oral cagrisema — 70%+ market share in GLP-1","VKTX":"High-upside mid-cap developer with promising oral/subcutaneous dual GLP-1/GIP agonists"},"second_order_effects":{"Food companies":"Adapting portfolios — smaller portions, protein-rich products for GLP-1 users","Medtech":"Reduced bariatric surgery volume (ISRG exposure), offset by cardiology procedures","Managed care":"UNH/CVS facing reimbursement cost pressure but long-term lower chronic disease burden"},"risks":["Reimbursement pressures — insurance exclusions and price controls limiting penetration","Tolerability and muscle loss — side effects causing high patient discontinuation rates"],"time_horizon":"5-10 years","conviction":"high"}}